CELC Celcuity Therapeutics: צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים

Celcuity Inc. develops advanced cellular tests for the personalized selection of anticancer therapies. Changes in quarterly EPS dynamics, as shown on this chart from GURU.Markets, indicate that the latest figure is -45.20. Stable management is focused on clinical trials of targeted drugs. The analysis of live tumor cells minimizes risks, allowing physicians to accurately determine effective drug combinations.

Quarterly EPS growth measures the dynamics of net income per share, filtering out market noise following the publication of 10-Q reports. By analyzing the current quarterly EPS growth rate, an investor assesses the monetization efficiency of Celcuity Inc. intellectual property. Collaborations with Pfizer and Roche on targeted therapy directly impact this metric through the cost of joint research. A stable trend confirms the resilience of the business model, eliminating the risk of purchasing the asset at the peak of emotional optimism.